Phase I trial

Hong Kong, China, August 10, 2026 Ascletis Pharma Inc. has announced the initiation of two Phase I clinical studies...

SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 3, 2026 Adlai Nortye Ltd. has advanced its oncology pipeline after submitting a...

PORTLAND, Ore., July 29, 2026 Trace Biosciences, Inc. has secured a strategic investment from Axogen, Inc. to accelerate clinical...

DELFT, The Netherlands, June 30, 2026 AdJane, a clinical-stage vaccine platform company, has announced the publication of first-in-human Phase...

SHANGHAI, China, July 2, 2026 Multitude Therapeutics Co., Ltd. announced encouraging interim Phase I clinical results for its CDH17-directed...

HONG KONG, June 23, 2026 Ascletis Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...

TOKYO, Japan, June 2026 Heartseed Inc. announced the successful treatment of the first patient in its Phase I/II EMERALD...

SHANGHAI and HONG KONG, China, June 10, 2026 Antengene announced that China’s National Medical Products Administration (NMPA) has approved...

CARY, N.C. and BRADENTON, Fla., May 20, 2026 Continuity Biosciences has announced the initiation of a Phase I first-in-human...

SAN FRANCISCO, May 6, 2026 Artera announced that the U.S. Food and Drug Administration (FDA) has granted clearance for...